Allena Pharmaceuticals Inc (NASDAQ:ALNA) – Equities researchers at B. Riley issued their FY2023 earnings estimates for Allena Pharmaceuticals in a research report issued to clients and investors on Friday, July 26th, according to Zacks Investment Research. B. Riley analyst M. Mamtani expects that the company will post earnings per share of ($0.37) for the year.
Allena Pharmaceuticals (NASDAQ:ALNA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.01).
A number of other equities research analysts have also issued reports on the stock. Roth Capital decreased their target price on shares of Allena Pharmaceuticals from $61.00 to $31.00 in a research note on Thursday, August 8th. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Allena Pharmaceuticals in a research note on Monday, August 12th. Cowen reissued a “buy” rating on shares of Allena Pharmaceuticals in a research note on Friday, August 9th. ValuEngine raised shares of Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Credit Suisse Group reissued an “outperform” rating and set a $26.00 target price on shares of Allena Pharmaceuticals in a research note on Monday, August 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Allena Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $23.14.
Allena Pharmaceuticals stock traded up $0.55 during midday trading on Monday, reaching $4.55. The stock had a trading volume of 60,886 shares, compared to its average volume of 78,011. The firm’s fifty day simple moving average is $4.36 and its two-hundred day simple moving average is $5.57. Allena Pharmaceuticals has a twelve month low of $3.62 and a twelve month high of $12.00. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.80 and a quick ratio of 6.80. The firm has a market cap of $93.88 million, a price-to-earnings ratio of -2.65 and a beta of 1.98.
Institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers bought a new position in shares of Allena Pharmaceuticals during the 4th quarter worth about $78,000. Wedbush Securities Inc. bought a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth about $63,000. Deutsche Bank AG increased its holdings in shares of Allena Pharmaceuticals by 8.2% during the 4th quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock worth $151,000 after purchasing an additional 2,118 shares during the period. Jane Street Group LLC bought a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth about $116,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Allena Pharmaceuticals during the 2nd quarter valued at about $137,000. Institutional investors and hedge funds own 67.89% of the company’s stock.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company’s lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.